✦ LIBER ✦

O-077 Gemcitabine/cisplatin plus bevacizumab or placebo in advanced malignant mesothelioma: A multi-center, double-blind placebo-controlled, randomized phase II trial

✍ Scribed by Kindler, H.; Lu, C.; Gandara, D.; Stevenson, J.; Krug, L.; Janne, P.; Gitlitz, B.; Karrison, T.; Stadler, W.; Vokes, E.

Book ID: 118572624
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 284 KB
Volume: 49
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(05)80210-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

VANTAGE 014: Vorinostat (V) in Patients

VANTAGE 014: Vorinostat (V) in Patients With Advanced Malignant Pleural Mesothelioma (MPM) who Have Failed Prior Pemetrexed and Either Cisplatin or Carboplatin Therapy: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial

✍ L.M. Krug; H. Kindler; H. Calvert; C. Manegold; A.S. Tsao; D. Fennell; G.M. Lubi 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 64 KB

Phase III, Randomized, Double-Blind, Pla

Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non-Small-Cell Lung Cancer

✍ Paz-Ares, L. G.; Biesma, B.; Heigener, D.; von Pawel, J.; Eisen, T.; Bennouna, J 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 163 KB

Randomized, Double-Blind, Placebo-Contro

Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer

✍ Spigel, D. R.; Burris, H. A.; Greco, F. A.; Shipley, D. L.; Friedman, E. K.; Wat 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 161 KB

A randomized, multi-Center, double-blind

A randomized, multi-Center, double-blind, placebo-controlled phase II/III trial to evaluate the efficacy, tolerability and safety of MRX-7EAT Etodolac-Lidocaine Topical Patch in the treatment of pain

✍ Kuwabara, Y.; Hamamoto, H.; Hikake, S.; Miwa, Y. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 95 KB

5002 ORAL Results from a Phase II random

5002 ORAL Results from a Phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer

✍ Makhija, S.; Glenn, D.; Ueland, F.; Dizon, D.; Paton, V.; Lin, C.Y.; Amler, L.; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 77 KB

A phase II randomized, double-blind, pla

A phase II randomized, double-blind, placebo-controlled multicenter study of recombinant human interleukin-12 for the treatment of chronic hepatitis C virus infection in patients non-responsive to previous treatment with interferon-alpha with or without ribavirin: Paul J Pockros, John G McHutchison, Scripps Clinic, La Jolla, CA; Chris O'Brien, University of Miami, Miami, FL; Myron Tong, Huntingon Medical Research Institute, Pasadena, CA; Coleman Smith, Minnesota Clinical Research Center, St. Paul, MN; Vinod Rustgi, Metropolitan Research Group, Fairfax, VA; Robert L Carithers, University of Washington Medical Center, Seattle, WA; Elizabeth Olek, Genetics Institute, Cambridge, MA

📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB